In contrast, SF3A3 knockdown reversed these effects, sensitizing cells to cisplatin.[35] These findings demonstrate that SF3A3 exerts its oncogenic and chemoprotective effects primarily through c‐FOS regulation, positioning SF3A3 as a key driver of endometrial cancer progression and a potential therapeutic target to overcome chemotherapy resistance. The gene discussed is FOS; the disease is endometrial cancer.